ANIKA THERAPEUTICS INC (ANIK)
Sector: Health Care
2026 Annual Meeting Analysis
ANIKA THERAPEUTICS INC · Meeting: June 18, 2026
Directors FOR
1
Directors AGAINST
2
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class III Directors
Against Analysis
Mr. Fischetti has served since April 2023 (over 24 months), meaning the TSR trigger applies to his tenure: Anika's stock lost 42.8% over three years while the company's disclosed peer group gained a median of 29.2%, a gap of 72 percentage points — far exceeding the 20-percentage-point threshold that applies when a company's absolute return is negative, warranting a vote against.
Mr. Henneman has served since September 2020, so the TSR trigger fully applies; the three-year underperformance gap of 72 percentage points versus the peer group median is severe. However, the policy's five-year mitigant requires checking the longer track record: over five years Anika underperformed the same peer group by only 13.4 percentage points, which does not exceed the 20-percentage-point threshold for a company with a negative absolute five-year return, so the vote is downgraded from AGAINST to FOR — the recent three-year trough appears to sit within an otherwise less-severe longer-term picture.
For Analysis
Mr. Griffin joined the board in February 2026, which is less than 24 months before the meeting date, so he is fully exempt from the TSR trigger under policy; he also brings directly relevant operating experience as the company's current CEO.
Of the three Class III nominees, Stephen Griffin is exempt from the TSR trigger due to his recent appointment (February 2026). John Henneman triggers the three-year underperformance screen but benefits from the five-year mitigant, resulting in a FOR vote. Gary Fischetti triggers the three-year screen without the benefit of a mitigating five-year track record (his tenure began in 2023), resulting in an AGAINST vote.
Say on Pay
✓ FORCEO
Cheryl R. Blanchard, Ph.D.
Total Comp
$4,887,318
Prior Support
77%%
The prior say-on-pay vote received 77% support (above the 70% threshold that would require a response), and the company made visible program improvements in response to stockholder feedback, including increasing the performance-based share of the CEO's equity awards from 50% to 67% and adding specific stock-price hurdles. The company discloses that approximately 85% of CEO pay and 67% of other named executive officers' pay was variable and at-risk, which satisfies the policy's requirement that at least 50-60% of senior executive compensation be performance-based. The annual bonus paid out at exactly 100% of target based on a balanced scorecard with measurable financial and strategic metrics including revenue, adjusted EBITDA, and regulatory milestones, and the company acknowledges that CEO realizable compensation was 53% below reported compensation due to stock price underperformance, demonstrating that the incentive structure is actually reducing executive pay in line with shareholder experience.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
N/A
Audit Fees
$911,272
Non-Audit Fees
$142,767
Non-audit fees (audit-related fees of $40,250 plus tax fees of $100,872 plus other fees of $1,895 = $142,767) represent approximately 15.7% of audit fees ($911,272), well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the filing so no tenure trigger is fired; Deloitte is a Big 4 firm appropriate for a company of Anika's size and complexity.
Overall Assessment
The 2026 Anika Therapeutics annual ballot presents five proposals; the most consequential governance concern is the company's severe three-year stock price underperformance relative to its disclosed peer group (-72 percentage points), which triggers an AGAINST vote for director Gary Fischetti while the five-year mitigant rescues John Henneman to a FOR. The say-on-pay vote earns a FOR based on a predominantly at-risk pay structure, visible program improvements made in response to last year's 77% support level, and the company's acknowledgment that realizable CEO compensation was materially below reported values due to stock price weakness.
Compensation Peer Group
17 companies disclosed in 2026 proxy filing